The efficacy of CAR T-cell therapy for r/r B-ALL using different approaches revealed that targeting both the CD22 and CD19 showed a positive trend of remission, as reflected by MRD-CR.
← all excerpts
Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
1
—
—